Regeneron, Bayer strike another Eylea combo deal
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) granted Bayer AG (Xetra:BAYN) exclusive ex-U.S. rights to a combination including Regeneron's nesvacumab ( REGN910) and its ophthalmic drug Eylea aflibercept ophthalmic solution. The combination, formulated as a single intravitreal injection, is in Phase II testing to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
Nesvacumab is a mAb against angiopoietin 2 ( ANG2; ANGPT2). Eylea is a human fusion protein that binds all forms of VEGF-A and placental growth factor ( PGF; PlGF). Bayer has ex-U.S. rights to Eylea from Regeneron. Eylea's 2015 ex-U.S. sales were $1.4 billion. Outside of Japan, Regeneron and Bayer split ex-U.S. costs and profits. Regeneron receives a royalty on Japanese sales. ...